Clinical Trials on Advanced KRAS G12D Mutant Solid Tumors in United Kingdom
Total 1025 results
-
AmgenActive, not recruitingKRAS p.G12C Mutant Advanced Solid TumorsUnited States, France, Canada, Spain, Belgium, Korea, Republic of, Austria, Australia, Hungary, Greece, Germany, Japan, Romania, Switzerland, Brazil, Portugal
-
Lupin Ltd.CompletedA Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid TumorsNRAS/KRAS Mutated Advanced or Metastatic Refractory Solid TumorsUnited Kingdom, Netherlands, Belgium
-
Frontier Medicines CorporationRecruitingColorectal Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Metastatic Solid Tumor | Solid Tumor, Adult | Unresectable Solid Tumor | KRAS G12C | Advanced Solid Tumors With KRAS G12C MutationsUnited States
-
Revolution Medicines, Inc.RecruitingNon-Small Cell Lung Cancer, NSCLC | KRAS, NRAS, HRAS-mutated NSCLC | KRAS G12C-mutated Solid Tumors, Lung Cancer | Lung Cancer Stage IV, Advanced Solid Tumor, CancerUnited States
-
Turning Point Therapeutics, Inc.TerminatedAdvanced Solid Tumor | Metastatic Solid Tumor | KRAS Mutation-Related TumorsUnited States
-
Georgetown UniversityImmune System Key LtdRecruitingSolid Tumor | KRAS Mutation-Related TumorsUnited States
-
Boehringer IngelheimActive, not recruitingSolid Tumors, KRAS MutationSpain, United Kingdom, United States, Belgium
-
AstraZenecaParexelTerminatedAdvanced Solid TumorsUnited Kingdom
-
BeiGeneCompletedAdvanced Solid TumorsUnited Kingdom
-
Novartis PharmaceuticalsRecruitingAdvanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,MelanomaNetherlands, Korea, Republic of, Spain, Taiwan, Japan, Italy, United States, Singapore, Canada
-
Boehringer IngelheimActive, not recruitingSolid Tumors, KRAS Mutation; SOS1United States, Netherlands, Germany
-
PharmaMarCompletedAdvanced Solid TumorsUnited Kingdom, Switzerland
-
ArQule, Inc. (a wholly owned subsidiary of Merck...CompletedCancer, Advanced Solid TumorsUnited Kingdom
-
PfizerCompletedLocally Advanced or Metastatic NRAS Mutant MelanomaUnited States, Australia, Germany, Italy, Netherlands
-
Cancer Research UKCompleted
-
PharmaMarCompletedSpecific Advanced Solid TumorsSpain, United Kingdom
-
Calithera Biosciences, IncCompletedNSCLC | Solid Tumors | KRAS Gene Mutation | CRCUnited States
-
Nerviano Medical SciencesTerminatedAdvanced/Metastatic Solid TumorsUnited Kingdom, France
-
zr Pharma & GmbHCompletedAdvanced Solid TumorsUnited Kingdom
-
Taiho Oncology, Inc.TerminatedAdvanced Solid TumorsItaly, Spain, United States, Netherlands, United Kingdom
-
Eisai Inc.Completed
-
Bristol-Myers SquibbTerminatedAdvanced Solid TumorsUnited States, Canada, United Kingdom
-
Boehringer IngelheimRecruitingSolid Tumor, KRAS MutationUnited States, Taiwan, Japan
-
AstraZenecaCompletedAdvanced Solid Metastatic TumorUnited Kingdom
-
Novartis PharmaceuticalsCompletedAdvanced Solid TumorsSwitzerland, Netherlands, United States, United Kingdom
-
Cancer Research UKTerminatedAdvanced Solid TumoursUnited Kingdom
-
OSI PharmaceuticalsCompletedAdvanced Solid TumorsUnited States, United Kingdom
-
AstraZenecaParexelTerminatedAdvanced Solid TumoursUnited Kingdom, United States
-
Stemline Therapeutics, Inc.CompletedStudy of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors With Advanced Solid TumorsAdvanced Solid TumorUnited Kingdom
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Heidelberg Pharma AGTerminatedAdvanced Solid TumoursUnited Kingdom
-
AmgenRecruitingAdvanced Solid Tumors | Kirsten Rat Sarcoma (KRAS) pG12C MutationUnited States, Italy, Taiwan, Spain, United Kingdom, Australia, Austria, Germany, Belgium, Japan, Netherlands, Korea, Republic of, Canada
-
Novartis PharmaceuticalsCompletedAdvanced Solid TumorsSwitzerland, Sweden, Netherlands, United States, United Kingdom
-
UCB Biopharma SRLCompletedAdvanced Solid TumorsUnited States, United Kingdom
-
AstraZenecaSyneos HealthCompletedAdvanced Solid TumoursUnited States, Spain, Korea, Republic of, United Kingdom
-
Heidelberg Pharma AGTerminatedAdvanced Solid TumoursUnited Kingdom
-
Taiho Oncology, Inc.CompletedAdvanced Solid TumorsUnited States, United Kingdom, Italy
-
Affini-T Therapeutics, Inc.RecruitingColorectal Cancer | Non-Small Cell Lung Cancer | Solid Tumor | Pancreatic Ductal Adenocarcinoma | KRAS G12VUnited States
-
T-knife GmbHTerminatedAdvanced Solid TumorsGermany, Belgium, Spain, Netherlands, United Kingdom
-
Exscientia AI LimitedGT Apeiron LLCRecruitingAdvanced Solid TumorUnited Kingdom, Belgium
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
ADC Therapeutics S.A.Active, not recruitingAdvanced Solid TumorsUnited States, Spain, United Kingdom
-
Immunocore LtdTerminatedSelect Advanced Solid TumorsUnited States, Canada, United Kingdom
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid Tumor | Advanced Solid TumorSpain, United States, Netherlands, United Kingdom
-
Immunocore LtdTerminatedSelect Advanced Solid TumorsUnited States, United Kingdom, Spain
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
BioNTech SEGenmabRecruitingAdvanced Malignant Solid TumorUnited States, United Kingdom
-
Vall d'Hebron Institute of OncologyTaisho Pharmaceutical Co., Ltd.; Roche Pharma AG; Iqvia Pty Ltd; Janssen, LPRecruitingAdvanced Solid TumorSpain, France, Germany, Netherlands, Sweden, United Kingdom, Italy
-
Erasca, Inc.RecruitingAdvanced or Metastatic NRAS-mutant MelanomaUnited States
-
Taiho Oncology, Inc.TerminatedAdvanced or Metastatic Solid Tumors Irrespective of Gene Alterations | Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating MutationsUnited States, United Kingdom, Austria, France